Buy the Dip Monday: When Analyst Targets Imply 776% Upside and the Yield Is 17%
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.
Sign in →6. VanEck Gold Miners ETF (GDX)
P/E: 17.02 | Earnings yield: 5.9% | 52w drawdown: -39.2%
GDX offers diversified exposure to gold miners at a 17.02× P/E while sitting 39% below its 52-week high, a drawdown that aligns with individual gold equities on this screen. The earnings yield spread of 1.3% over the 10-year Treasury provides modest relative value, and the ETF structure eliminates single-name operational risk.
The ETF carries no FCF yield, dividend yield, or debt metrics because it aggregates underlying holdings, and the 39% drawdown persists despite rising gold prices, suggesting the market expects miners to lag bullion. Recent news highlights outflows into inverse gold miner products like DUST, which jumped 28% in a month.
The setup here is a pure commodity-leverage play with no margin of safety from cash flow or dividends. If gold prices stall, the 39% drawdown extends further, and the 17× multiple offers no valuation cushion compared to single-name miners trading at 12× or less on this screen.
7. Baker Hughes Company (BKR)
P/E: 17.95 | Earnings yield: 5.6% | 52w drawdown: -20.2%
Baker Hughes trades at an 17.95× P/E with a 12.8% ROIC and 4.6% FCF yield, supported by a 1.6% dividend yield and 0.6% shareholder yield. Analysts see $71.52 as fair value, implying 27% upside from the current $56.17 price, and the company reports earnings July 26 with consensus at $0.48 EPS and $6.5B revenue.
Maria C. Borras and Lorenzo Simonelli filed Form 4 transactions in late June and early July, and the U.S. rig count rose seven units as oil prices climbed back above $80 per barrel. The 2.3% short interest and 20% drawdown suggest modest bearish positioning, and the debt-to-equity of 0.86 is manageable for an energy services company.
Revenue declined 0.3% year-over-year, and the earnings yield spread of 1.0% over the 10-year Treasury is the narrowest on this screen, offering no meaningful relative value. The 17.95× multiple sits at the high end of the value screen, and the company's exposure to oilfield services means earnings volatility if crude prices reverse.
8. GSK plc (GSK)
P/E: 13.36 | Earnings yield: 7.5% | 52w drawdown: -17.1%
GSK trades at a 13.36× P/E with a 19.9% ROIC, 4.1% revenue growth, and a 4.6% FCF yield, supported by a 3.5% dividend yield and 1.4% shareholder yield. Analysts see $57.94 as fair value, implying 13% upside from the current $51.18 price, and the company completed a $10.6B acquisition of Nuvalent while delivering promising interim data for Jemperli in rectal cancer.
Ron Squarer, Christy J. Oliger, and Grant C. Bogle each filed Form 4 transactions in mid-July, and short interest at 0.3% of float signals minimal bearish conviction. The normalized 10-year P/E of 14.32 aligns closely with the current 13.36× multiple, suggesting the valuation is fair on a long-cycle basis.
Debt-to-equity of 1.17 is elevated for a large-cap pharma, and the 17% drawdown persists despite positive pipeline news, signaling either integration concerns from the Nuvalent acquisition or market skepticism about the oncology strategy. The earnings yield spread of 2.9% over the 10-year Treasury provides modest relative value but no dramatic margin of safety.
What to Watch
• July 23: Newmont earnings with consensus at $1.99 EPS and $6.3B revenue; gold prices and cost guidance will determine whether the 59% analyst upside target is realistic.
• July 26: Baker Hughes reports with consensus at $0.48 EPS and $6.5B revenue; oilfield services activity and crude price assumptions will frame the 27% upside case.
• July 28: KLA earnings with consensus at $1.00 EPS and $3.6B revenue; semiconductor capex guidance clarifies whether the 776% analyst target reflects genuine opportunity or stale estimates after the 90% drawdown.
• July 30: First Solar reports with consensus at $2.82 EPS and $1.1B revenue; module pricing and 2027 demand visibility will test whether the 14% upside target holds despite 8.5% short interest and 100% insider selling over six months.
Go Deeper
The value screener hunts for earnings yields above the 10-year Treasury, low normalized P/Es, and strong cash flow at depressed prices.
Check out the full screener →
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full Buy the Dip screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →Or start with the free Market Brief Digest
Where the market stands before the open, in plain language, every trading day. No account needed.